AdvanCell
Changing the Course of Cancer Treatment
Sydney, Australia · Founded 2019 · $427.0M raised
- Headquarters
- Sydney
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- advancell.com.au
- Total Funding
- $427.0M
- Last Round
- $315.0M Venture RoundJul 2026
- Rounds
- 3
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer using lead-212 (212Pb). Headquartered in Sydney, Australia with a growing US presence, the company operates a vertically integrated platform for manufacturing and delivering 212Pb-based therapies, with a lead program targeting PSMA for prostate cancer.
Summary
AdvanCell is a Biotech company based in Sydney, Australia, founded in 2019. It has raised $427.0M in total across 3 rounds, most recently a $315.0M Venture Round in Jul 2026. Investors include Morningside Group.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jul 2026
Sign up to see all 3 events
Funding: Series B through Venture Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/advancel"><img src="https://indexed.vc/api/badge/company/advancel" alt="AdvanCell on Indexed.vc" width="260" height="76" /></a>